Body mass index has its limitations, but for now it’s the metric medicine often defaults to when predicting weight-related health problems. A new tool promises to better define who’s at […]
Read MoreHims & Hers won’t sell compounded version of Novo’s obesity pill
Hims & Hers said Saturday it will stop selling what it claims to be a cheaper, compounded version of Novo Nordisk’s obesity pill on its telehealth platform, after health officials […]
Read MoreRoche moves obesity drug to pivotal trials after mid-stage success
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. Roche plans to launch Phase 3 studies of its leading obesity […]
Read MoreSTAT+: Kennedy, a longtime pharma critic, embraces Trump deal to expand access to obesity drugs
WASHINGTON — Health secretary Robert F. Kennedy Jr. was uncharacteristically chummy with pharma executives at the White House on Thursday as he cheered the Trump administration’s plan for lowering obesity medication […]
Read MoreNovo Nordisk’s obesity drug Wegovy cleared to treat live disease MASH
Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators on Friday to treat an increasingly common liver disease, adding to the list of conditions for which the blockbuster therapy […]
Read MoreNovo Nordisk’s next-gen obesity drug results a letdown for investors
CHICAGO — Late-stage results of Novo Nordisk’s obesity candidate CagriSema suggest the drug is comparable to Eli Lilly’s Zepbound on safety and efficacy, further data indicating that CagriSema may not […]
Read MoreReadout LOUD podcast: FDA AI experiment, Novo trails in obesity
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech […]
Read MoreWe’re reading about FDA hold on Amgen obesity drug, Canada drugs
Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it […]
Read More